Precision oncology player Nuvectis Pharma receives a buy recommendation and price target with a significant premium from Lucid Capital Markets. Report highlights Nuvectis’ potential to generate hundreds of millions of dollars in revenue and notes upcoming phase 1a clinical data as a potential catalyst

NEW YORK, February 27, 2025--(BUSINESS WIRE)--Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (Nasdaq: NVCT) with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need.

Lucid's report emphasizes the strong potential of NXP900, which is currently in Phase 1 clinical trials and has shown an encouraging safety profile while continuing dose escalation. The firm projects peak non-risk-adjusted sales of over $900 million for NXP900 across multiple cancer indications by 2041.

Additionally, Nuvectis’ second asset, NXP800, a GCN2 activator, is in Phase 1b trials targeting ARID1a-mutated ovarian cancer. Although previous dosing regimens required adjustments due to safety concerns, the report views NXP800 as a potential upside with limited downside risk. The company’s financial position is another key factor supporting the Buy rating. With cash and equivalents of $18.5 million as of year-end 2024 and a recent $15.5 million public offering in Q1 2025, Lucid forecasts that Nuvectis has a cash for a significant period of time, allowing it to continue advancing its clinical programs.

Lucid firm sees upcoming Phase 1a data in 2025 as a potential catalyst for the stock, along with the planned initiation of a Phase 1b trial and combination studies later this year.

Market News Alerts is not responsible for the price target nor does it endorse it. Readers are advised to refer to the full report on various systems and the disclaimers/disclosures it may be subject to.

Recent News from Nuvectis

• Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights
• Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
• Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Nuvectis Pharma and was produced as part of their paid subscription to Wall Street Wire. This alert has not been reviewed or approved by Nuvectis Pharma prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250227805907/en/

Contacts

Market Alerts News Desk
media.globalmarkets@gmail.com